Literature DB >> 1727737

Effect of Mg2+ on Na(+)-dependent inositol transport. Role for Mg2+ in etiology of diabetic complications.

G Grafton1, C M Bunce, M C Sheppard, G Brown, M A Baxter.   

Abstract

Diabetes mellitus is associated with a significant reduction in the serum concentration of Mg2+. Several studies have suggested that hypomagnesemia may be implicated in the etiology of diabetic complications; however, no mechanism has been proposed. This study demonstrates that Mg2+ is a positive effector of inositol transport and is capable of promoting a 2.5-fold increase in the affinity of the transporter for inositol. Analysis of the kinetics of inositol transport shows that, at physiological concentrations of inositol, the reductions in Mg2+ concentrations that occur in diabetic patients would result in a significant decline in the rate of inositol transport (1.5- to 2-fold). We suggest that hypomagnesemia may be linked to the development of diabetic complications via reduction in the rate of inositol transport and subsequent intracellular inositol depletion. This assertion allows hypomagnesemia and the polyol theory to be unified into one mechanistic model for the development of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727737     DOI: 10.2337/diab.41.1.35

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

1.  Hypomagnesaemia and type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  H W de Valk
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

2.  Hypomagnesaemia in childhood IDDM and risk of nephropathy.

Authors:  I Arslanoğlu; H Günöz; R Bundak; N Saka
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

3.  Magnesium attenuates chronic hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat model of diabetic neuropathic pain.

Authors:  L J Rondón; A M Privat; L Daulhac; N Davin; A Mazur; J Fialip; A Eschalier; C Courteix
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

4.  Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease.

Authors:  Yusuke Sakaguchi; Hirotsugu Iwatani; Takayuki Hamano; Kodo Tomida; Hiroaki Kawabata; Yasuo Kusunoki; Akihiro Shimomura; Isao Matsui; Terumasa Hayashi; Yoshiharu Tsubakihara; Yoshitaka Isaka; Hiromi Rakugi
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

5.  Magnesium metabolism and its disorders.

Authors:  R Swaminathan
Journal:  Clin Biochem Rev       Date:  2003-05

6.  Regulation of myo-inositol transport during the growth and differentiation of thyrocytes: a link with thyroid-stimulating hormone-induced phospholipase A2 activity.

Authors:  G Grafton; M A Baxter; M C Sheppard; M C Eggo
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

7.  Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease.

Authors:  Yusuke Sakaguchi; Tatsuya Shoji; Terumasa Hayashi; Akira Suzuki; Morihiro Shimizu; Kensuke Mitsumoto; Hiroaki Kawabata; Kakuya Niihata; Noriyuki Okada; Yoshitaka Isaka; Hiromi Rakugi; Yoshiharu Tsubakihara
Journal:  Diabetes Care       Date:  2012-04-12       Impact factor: 19.112

8.  Hypomagnesemia in persons with type 1 diabetes: associations with clinical parameters and oxidative stress.

Authors:  Peter R van Dijk; F Waanders; Jiedong Qiu; Hannah H R de Boer; H van Goor; H J G Bilo
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-29       Impact factor: 3.565

Review 9.  Magnesium in Prevention and Therapy.

Authors:  Uwe Gröber; Joachim Schmidt; Klaus Kisters
Journal:  Nutrients       Date:  2015-09-23       Impact factor: 5.717

10.  Low serum magnesium levels are associated with impaired peripheral nerve function in type 2 diabetic patients.

Authors:  Chen Chu; Weijing Zhao; Yinan Zhang; Lu Li; Jingyi Lu; Lan Jiang; Congrong Wang; Weiping Jia
Journal:  Sci Rep       Date:  2016-09-07       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.